Journal article

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Abstract:: Background 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment.

Methods The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk stage II and stage III colorectal can... Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Iveson, T., Kerr, R., Saunders, M., Cassidy, J., Hollander, N., Tabernero, J., Haydon, A., Glimelius, B., Harkin, A., Allan, K., McQueen, J., Scudder, C., Boyd, K., Briggs, A., Waterston, A., Medley, L., Wilson, C., Ellis, R., Essapen, S., … Paul, J. (2018). 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology, 19(4), 562–578.

MLA Style

Iveson, T., et al. “3 Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Combination Therapy for Colorectal Cancer (SCOT): an International, Randomised, Phase 3, Non-Inferiority Trial.” Lancet Oncology, vol. 19, no. 4, Elsevier, 2018, pp. 562–78.

Chicago Style

Iveson, T, R Kerr, M Saunders, J Cassidy, N Hollander, J Tabernero, A Haydon, et al. 2018. “3 Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Combination Therapy for Colorectal Cancer (SCOT): an International, Randomised, Phase 3, Non-Inferiority Trial.” Lancet Oncology 19 (4): 562–78.
Share
Print

Access Document

Files:: 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine com...

(Preview, Version of record, pdf, 1.9MB, Terms of use)

Publisher copy:: 10.1016/S1470-2045(18)30093-7

Authors

+ Iveson, T More by this author

Role:: Author

+ Kerr, R More by this author

Institution:: University of Oxford
Division:: Medical Sciences Division
Department:: Oncology
Role:: Author

+ Saunders, M More by this author

Role:: Author

+ Cassidy, J More by this author

Role:: Author

+ Hollander, N More by this author

Role:: Author

More authors...

+ Cancer Research More from this funder

+ Medical Research Council More from this funder

Publisher:: Elsevier
Journal:: Lancet Oncology More from this journal
Volume:: 19
Issue:: 4
Pages:: 562-578
Publication date:: 2018-03-28
Acceptance date:: 2018-01-25
DOI:: 10.1016/S1470-2045(18)30093-7
EISSN:: 1474-5488
ISSN:: 1470-2045
Pmid:: 29611518

Language:: English
Pubs id:: pubs:833619
UUID:: uuid:4d403693-354c-4441-80b0-0109a601be79
Local pid:: pubs:833619
Source identifiers:: 833619
Deposit date:: 2019-03-11

Terms of use

Copyright holder:: Iveson et al
Copyright date:: 2018
Notes:: © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP